Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial

NARecruitingINTERVENTIONAL
Enrollment

36,000

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

September 1, 2031

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

Contrast-enhanced mammography (CEM)

This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program

DIAGNOSTIC_TEST

Abbreviated MRI (AB-MRI)

This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program

Trial Locations (1)

Unknown

RECRUITING

UMC Utrecht, Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Ziekenhuisgroep Twente

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

Rijnstate Hospital

OTHER

collaborator

Zuyderland Medical Centre

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

Elisabeth-TweeSteden Ziekenhuis

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

collaborator

Jeroen Bosch Hospital

UNKNOWN

collaborator

Erasmus Medical Center

OTHER

collaborator

Albert Schweitzer Hospital

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Antoni van Leeuwenhoek Hospital

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Bevolkingsonderzoek Nederland

UNKNOWN

collaborator

Borstkankervereniging Nederland

UNKNOWN

lead

C.H. van Gils

OTHER

NCT06636370 - Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial | Biotech Hunter | Biotech Hunter